Skip to main content


Ocugenix is focused on the development and commercialization of therapeutics for ocular diseases caused by excessive fibrosis and blood vessels in the eye.

Ocugenix has developed therapies for two of the most common causes of late onset blindness affecting more than 12.5 million people every year, such as wet macular degeneration and diabetic retinopathy.  These diseases are caused by an aberrant wound response in the back of the eye. Ocugenix’s compound triggers the process of wound resolution to cause the regression of the excessive fibrosis and vasculature recruited to heal the wound. The ability to cause regression of the pathological vessels and fibrosis in AMD and DR offers the patient the best hope of restoring lost sight.